Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
about
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus.Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate CancerNew frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
P2860
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@en
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@nl
type
label
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@en
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@nl
prefLabel
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@en
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@nl
P2093
P2860
P356
P1433
P1476
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
@en
P2093
Danielle Carroll
James Harper
JoAnn Suzich
Mark S Galinski
Weijia Wang
Xing Cheng
P2860
P304
P356
10.1128/JVI.00136-16
P407
P50
P577
2016-03-23T00:00:00Z